Advertisement
YOU ARE HERE: LAT HomeCollectionsLeukine Drug
IN THE NEWS

Leukine Drug

FEATURED ARTICLES
BUSINESS
August 6, 1991 | BARRY STAVRO, TIMES STAFF WRITER
Amgen Inc. is outselling Immunex Corp. six to one in a marketing battle of rival new biotechnology drugs expected to become the next family of gene-spliced medical blockbusters. Analysts expect the drugs to have annual sales reaching $600 million industrywide in five years. The drugs are genetically produced laboratory copies of proteins found in the body that trigger the production of white blood cells, one of the body's key infection fighters.
ARTICLES BY DATE
BUSINESS
April 11, 1995 | Times Staff and Wire Reports
Setback for Drug Maker: Immunex Corp. failed to get a Food and Drug Administration advisory panel's backing for the most important use of its lead drug, Leukine. An FDA panel of medical experts said the increased risk of using Leukine for preventing a decline in white blood cells in cancer chemotherapy patients outweighs the apparent benefits.
Advertisement
BUSINESS
April 11, 1995 | Times Staff and Wire Reports
Setback for Drug Maker: Immunex Corp. failed to get a Food and Drug Administration advisory panel's backing for the most important use of its lead drug, Leukine. An FDA panel of medical experts said the increased risk of using Leukine for preventing a decline in white blood cells in cancer chemotherapy patients outweighs the apparent benefits.
BUSINESS
August 6, 1991 | BARRY STAVRO, TIMES STAFF WRITER
Amgen Inc. is outselling Immunex Corp. six to one in a marketing battle of rival new biotechnology drugs expected to become the next family of gene-spliced medical blockbusters. Analysts expect the drugs to have annual sales reaching $600 million industrywide in five years. The drugs are genetically produced laboratory copies of proteins found in the body that trigger the production of white blood cells, one of the body's key infection fighters.
BUSINESS
May 4, 2002 | DENISE GELLENE, TIMES STAFF WRITER
Immunex Corp. said Friday that Schering agreed to pay $380 million for Leukine, a drug used to treat the side effects of chemotherapy. The deal clears a regulatory hurdle in the way of Amgen Inc.'s pending acquisition of Immunex. Amgen has two drugs that are similar to Leukine, and one of them, Neupogen, dominates the market. In a research note, Prudential Securities analyst John Sonnier said the deal was a good one.
BUSINESS
December 18, 2001 | DENISE GELLENE, TIMES STAFF WRITER
Discussions that led to Amgen Inc.'s $16-billion deal Monday to buy biotechnology rival Immunex Corp. began casually, over cocktails between chief executives. From the famous sky lounge of the Mark Hopkins Hotel, 19 stories above San Francisco Bay, the two chief executives took in the panoramic views and mused about being at the top of the biotechnology world, or as Amgen CEO Kevin Sharer remembers, "if our two companies could come together in some way ...."
Los Angeles Times Articles
|